Microfluidic System Based High Throughput Drug Screening System for Curcumin/TRAIL Combinational Chemotherapy in Human Prostate Cancer PC3 Cells.
Microfluidic System Based High Throughput Drug Screening System for Curcumin/TRAIL Combinational Chemotherapy in Human Prostate Cancer PC3 Cells.
复制标题
DOI：
10.4062/biomolther.2014.078
复制
发表时间：
2014-07
影响因子：
3.7
通讯作者：
Kim J
中科院分区：
文献类型：
--
作者：
An D;Kim K;Kim J
我们已经开发了一个全自动的高通量药物筛选（HTDS）系统的基础上的微流控细胞培养阵列进行组合化疗。该系统具有64个可单独寻址的细胞培养室，其中可以通过两个微流体扩散混合器产生两种不同药物的顺序组合浓度。每个扩散混合器具有两个分别连接到介质和药物储器的集成微型泵，用于产生所需的组合，而不需要任何额外的设备来灌注溶液，例如注射泵。在将细胞接种到微流体装置中之后，细胞阵列在几天期间周期性地暴露于具有编程的LabVIEW系统的药物组合，而无需额外的处理，并且与先前的系统相比，该装置不需要连续产生溶液。因此，每个实验消耗的药物总量在每个储器中小于几百微升。通过研究姜黄素和肿瘤坏死因子-α相关的凋亡诱导配体（TRAIL）的组合治疗对前列腺癌PC 3细胞系的存活率证明了该系统的实用性。结果表明，该系统可用于筛选和优化药物组合与少量的试剂，对肿瘤细胞的组合化疗。
We have developed a fully automated high throughput drug screening (HTDS) system based on the microfluidic cell culture array to perform combinational chemotherapy. This system has 64 individually addressable cell culture chambers where the sequential combinatorial concentrations of two different drugs can be generated by two microfluidic diffusive mixers. Each diffusive mixer has two integrated micropumps connected to the media and the drug reservoirs respectively for generating the desired combination without the need for any extra equipment to perfuse the solution such as syringe pumps. The cell array is periodically exposed to the drug combination with the programmed LabVIEW system during a couple of days without extra handling after seeding the cells into the microfluidic device and also, this device does not require the continuous generation of solutions compared to the previous systems. Therefore, the total amount of drug being consumed per experiment is less than a few hundred micro liters in each reservoir. The utility of this system is demonstrated through investigating the viability of the prostate cancer PC3 cell line with the combinational treatments of curcumin and tumor necrosis factor-alpha related apoptosis inducing ligand (TRAIL). Our results suggest that the system can be used for screening and optimizing drug combination with a small amount of reagent for combinatorial chemotherapy against cancer cells.
登录
查看更多内容
DOI：
10.1039/c3an00671a
发表时间：
2013-10-07
期刊：
The Analyst
影响因子：
--
作者：
Graf NJ;Bowser MT
通讯作者：
Bowser MT
影响因子：
6.1
作者：
Neils, C;Tyree, Z;Folch, A
通讯作者：
Folch, A
影响因子：
9.7
作者：
Barua, Sutapa;Linton, Rebecca S.;Rege, Kaushal
通讯作者：
Rege, Kaushal
影响因子：
6.1
作者：
Kim, Jeongyun;Hegde, Manjunath;Jayaraman, Arul
通讯作者：
Jayaraman, Arul
影响因子：
2.8
作者：
Shankar, S;Chen, XF;Srivastava, RK
通讯作者：
Srivastava, RK